Streetbeat News

Equity Actions

SHEL

Shell forecasts a capital expenditure (Capex) of $22 billion to $25 billion for 2024. The company also projects an adjusted earnings outlook with a net expense of $1.5 billion to $2.1 billion.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 7:28 am

SHEL

Shell has announced a 4% increase in its quarterly dividend to $0.344 per ordinary share and $0.688 per ADS, in line with its progressive dividend policy. Additionally, Shell is initiating a $3.5 billion share buyback program over the next three months. The ex-dividend dates for ADSs and ordinary shares are set for February 15, 2024, with the payment date on March 25, 2024.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 7:23 am

SHEL

Shell plc has initiated a $3.5 billion share buyback programme to reduce its issued share capital. The programme is set to last around three months, with the intention to complete it before the Q1 2024 results announcement on May 2, 2024. All repurchased shares will be cancelled.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 7:13 am

TAK

Takeda Pharmaceutical Company Limited (NYSE:TAK) has announced that CFO Costa Saroukos will step down on April 1, 2024, to return to Australia. Milano Furuta, currently president of Takeda's Japan Pharma Business Unit, will succeed him. Furuta will also be proposed as a candidate for election to the board of directors.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 7:02 am

TSLA

A Delaware court has dismissed Tesla CEO Elon Musk's $56 billion pay package, leading to potential renegotiations under investor scrutiny. Musk may appeal the decision, and if upheld, he must return $51 billion worth of unexercised options from his 2018 contract. The ruling calls for new independent board members to oversee Musk. Despite the setback, Musk is unlikely to leave Tesla due to his significant stake in the company. Additionally, Musk has polled about incorporating Tesla in Texas, with a majority favoring the move, but it's unclear if he will act on this.

Portfolio Pulse from Anan Ashraf

February 01, 2024 | 6:25 am

DNA

HOOD

PATH

TER

TSLA

TWLO

Ark Invest, led by Cathie Wood, has purchased $3.3 million worth of Robinhood Markets Inc (HOOD) shares and continued its investment in Tesla Inc (TSLA) with a $1.24 million purchase. The firm also sold shares in Twilio Inc (TWLO) and UiPath Inc (PATH), while investing in Ginkgo Bioworks Holdings Inc (DNA) and Teradyne Inc (TER). Ark's strategy reflects confidence in Robinhood's financial strategy and Tesla's long-term value, despite recent setbacks.

Portfolio Pulse from Benzinga Neuro

February 01, 2024 | 3:55 am

KPRX

Kiora Pharmaceuticals, Inc. (KPRX) has entered into a securities purchase agreement to raise up to $45 million. The deal includes $15 million in initial funding and up to $30 million more upon exercise of warrants by healthcare-focused institutional investors.

Portfolio Pulse from Charles Gross

January 31, 2024 | 11:43 pm

CTVA

Corteva Inc. (NYSE:CTVA) reported Q4 adjusted earnings of $0.15 per share, beating estimates of $0.06, but down from $0.16 year-over-year. Sales were $3.71 billion, exceeding expectations of $3.62 billion, yet down 3.08% from last year. The company experienced a net sales decrease of 3% and an 8% organic sales decrease, with a 9% volume decline in Latin America. Operating EBITDA increased by 4% to $386 million. Corteva forecasts 2024 net sales of $17.4-$17.7 billion, with adjusted earnings of $2.70-$2.90 per share, below the $3.01 estimate. The company announced a $1.0 billion share repurchase plan for 2024. After the earnings release, CTVA shares rose 4.55% to $47.55 in after-hours trading.

Portfolio Pulse from Ryan Gustafson

January 31, 2024 | 11:00 pm

PBI

Pitney Bowes has reached a cooperation agreement with Hestia Capital. Mary Guilfoile will retire from her role as Chair and from the Board after the 2024 Annual Meeting. The Board will elect a new Chair post-retirement. Pitney Bowes also announced the addition of two independent board members, William S. Simon and Jill Sutton, effective February 1, 2024. The next permanent CEO of Pitney Bowes will join the Board as its tenth member.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 10:51 pm

ATNF

180 Life Sciences Corp. has filed an S-1 form with the SEC for an offering of up to 13.95 million shares by a selling stockholder. The company itself will not receive any proceeds from the sale of these shares.

Portfolio Pulse from Charles Gross

January 31, 2024 | 10:35 pm